ViiV Healthcare announced positive 48-week data from the phase 3 ATLAS (N=616) and FLAIR (N=566) studies evaluating a long-acting injectable formulation of cabotegravir + rilpivirine in patients with HIV-1 infection.
Vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, was found to be superior to adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in achieving clinical remission in patients with moderately to severely active ulcerative colitis (UC), according to results from a phase 3b head-to-head trial.
Patients with low back pain or osteoarthritis who reported adverse drug reactions to nonsteroidal anti-inflammatory drugs have significantly higher odds of receiving prescriptions for opioids and developing opioid use disorder.
This article is part of Pulmonology Advisor‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019.…
OnabotulinumtoxinA treatment was found to reduce the frequency and severity of monthly headache days and to improve quality of life and disability in patients with chronic migraine with or without allodynia.
Refillable e-cigarettes demonstrate greater efficacy for smoking cessation than nicotine replacement therapy when both products are accompanied by behavioral support. A 2-group, multicenter, pragmatic, individually randomized controlled trial was conducted at 3 stop-smoking service sites in the United Kingdom as part of the National Health Service (NHS) between May 2015 and February 2018. Results of…
A team of investigators sought to identify the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma in individuals with cirrhosis.